Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01516398 · ClinicalTrials.gov registry record
Predictors of Pulmonary Hypertension Risk in Premature Infants With Bronchopulmonary Dysplasia
A clinical trial of Hypertension, Pulmonary and Bronchopulmonary Dysplasia (BPD), sponsored by Stanford University.
- Completed
- Registry status
- 40
- Enrollment target
- 2
- Study locations
NCT01516398 is a study of Hypertension, Pulmonary and Bronchopulmonary Dysplasia (BPD) that has completed, run by Stanford University. The registered enrollment target is 40 participants, below the 741-participant average among 10 other Hypertension, Pulmonary trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT01516398, a study of Hypertension, Pulmonary and Bronchopulmonary Dysplasia (BPD), has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
A lung condition called bronchopulmonary dysplasia (BPD) is a major cause of poor outcomes and death for premature infants. Infants with BPD are also at high risk for pulmonary hypertension (PH)-an important contributor to their condition. Previous research has suggested that a protein in the blood, endothelin-1 (ET-1), is associated with pulmonary disease. This study aims to investigate the incidence of PH and levels of ET-1 among premature babies with BPD. It will also potentially allow us to focus further research efforts and treatment towards these infants, some of our sickest patients at LPCH.
Conditions Studied
Study Locations (2)
California
- El Camino Hospital - Mountain View
- Lucile Packard Children's Hospital at Stanford - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2011-07 |
| Est. Completion | 2019-03-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01516398
The ClinicalTrials.gov registry entry for NCT01516398 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 741-participant average among 10 other Hypertension, Pulmonary trials with a reported enrollment target (95% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypertension, Pulmonary appearing as the primary indexed condition, and to 0 interventions.
NCT01516398 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01516398 about?
NCT01516398 is a clinical study titled "Predictors of Pulmonary Hypertension Risk in Premature Infants With Bronchopulmonary Dysplasia". A lung condition called bronchopulmonary dysplasia (BPD) is a major cause of poor outcomes and death for premature infants. Infants with BPD are also at high risk for pulmonary hypertension (PH)-an important contributor to their condition. Previous research has suggested that a protein in the blood,...
What is the current status of trial NCT01516398?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2011-07. Estimated completion is 2019-03-10.
What conditions does trial NCT01516398 study?
This clinical trial studies the following conditions: Hypertension, Pulmonary, Bronchopulmonary Dysplasia (BPD).
Who is sponsoring clinical trial NCT01516398?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01516398 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension, Pulmonary
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG
RECRUITING
-
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
RECRUITING · Phase 2
-
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
ACTIVE NOT RECRUITING · Phase 2
-
Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD
ACTIVE NOT RECRUITING · NA
-
Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.